한글목차

여성용 피임약 세계 시장 규모는 2024년에 150억 1,000만 달러로 평가되었으며, 2030년까지 CAGR은 6.24%로 강력한 성장이 예측됩니다.

이 시장에는 의도하지 않은 임신을 방지하고 여성의 생식 자율성을 지원하기 위해 고안된 다양한 제품과 기기가 포함됩니다. 피임 방법에는 피임약, 임플란트, 패치와 같은 호르몬 방법, 장벽 방법, 자궁 내 장치(IUD), 응급 피임약 등이 있습니다. 이 분야는 가족계획, 산모 사망률 감소, 여성 건강 지원에 있어 전 세계적으로 중요한 역할을 하고 있습니다. 생식 건강(성 및 생식 관련 건강)에 대한 인식의 증가, 의료 서비스 접근성 향상, 정부 지원책, 사회적 규범의 발전이 수요를 촉진하고 있습니다. 유엔인구기금(UNFPA)의 2022년 보고서에 따르면, 전 세계적으로 매년 약 1억 2,100만 건의 계획 외 임신이 발생하고 있어 효과적인 피임 솔루션의 필요성이 강조되고 있습니다. 제품 개발의 혁신과 문화적 태도의 변화는 세계 시장 확대를 지속적으로 촉진하고 있습니다.

시장 촉진요인

여성 역량 강화

주요 시장 과제

제한된 접근성과 인지도

주요 시장 동향

부작용이 적은 호르몬 피임약

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 고객의 소리

제5장 세계의 여성용 피임약 시장 전망

• 시장 규모 및 예측
  • 금액별
• 시장 점유율과 예측
  • 피임약별(경구 피임약, 피임 주사제, 국소 피임약, 살정자제)
  • 기구별(여성용 콘돔, 페서리 및 캡, 질 링, 피임 스펀지, 피하 피임 임플란트, 자궁내 피임기구(IUCD), 기타)
  • 지역별
  • 기업별(2024)
• 제품 시장 맵
  • 피임약별
  • 디바이스별
  • 지역별

제6장 북미의 여성용 피임약 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 북미 : 국가별 분석
  • 미국
  • 캐나다
  • 멕시코

제7장 유럽의 여성용 피임약 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 유럽 : 국가별 분석
  • 독일
  • 영국
  • 프랑스
  • 이탈리아
  • 스페인

제8장 아시아태평양의 여성용 피임약 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 아시아태평양 : 국가별 분석
  • 중국
  • 일본
  • 인도
  • 호주
  • 한국

제9장 남미의 여성용 피임약 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 남미 : 국가별 분석
  • 브라질
  • 아르헨티나
  • 콜롬비아

제10장 중동 및 아프리카의 여성용 피임약 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 중동 및 아프리카 : 국가별 분석
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트

제11장 시장 역학

• 성장 촉진요인
• 과제

제12장 시장 동향과 발전

• 최근 동향
• 인수합병
• 제품 출시

제13장 Porter's Five Forces 분석

• 업계내 경쟁
• 신규 참여의 가능성
• 공급업체의 능력
• 고객의 능력
• 대체품의 위협

제14장 경쟁 구도

• Bayer AG
• Mayer Laboratories Inc
• Pfizer Inc
• Mylan Pharmaceuticals Inc
• Teva Pharmaceutical Industries Ltd
• Organon & Co.
• Agile Therapeutics Inc
• Lupin Pharmaceuticals Inc
• The Female Health Company
• FUJI LATEX CO.,LTD.

제15장 전략적 제안

제16장 조사 회사 소개 및 면책사항

영문목차

The Global Female Contraceptive Market was valued at USD 15.01 billion in 2024 and is projected to witness strong growth with a CAGR of 6.24% through 2030F. This market includes a diverse range of products and devices designed to prevent unintended pregnancies and support reproductive autonomy for women. Contraceptive options include hormonal methods like pills, implants, and patches, as well as barrier methods, intrauterine devices (IUDs), and emergency contraceptives. The sector plays a key role in family planning, reducing maternal mortality, and supporting women's health globally. Growing awareness about reproductive health, increased healthcare accessibility, supportive government initiatives, and evolving social norms are propelling demand. According to the UNFPA's 2022 report, nearly 121 million unintended pregnancies occur globally each year, highlighting the critical need for effective contraceptive solutions. Innovation in product development and shifting cultural attitudes continue to strengthen market expansion worldwide.

Key Market Drivers

Women's Empowerment

Women's empowerment is a major catalyst for growth in the female contraceptive market, influencing healthcare decision-making and reproductive autonomy. Educated and informed women are better equipped to make decisions regarding contraception that align with their health needs and personal circumstances. Greater empowerment improves access to healthcare services, prompting more women to utilize family planning clinics and seek out reliable contraceptive options. As economic independence grows, women are increasingly able to afford and prioritize contraceptive products and services. This economic and social empowerment drives demand, encouraging pharmaceutical companies to innovate and expand contraceptive offerings to meet diverse needs across different populations.

Key Market Challenges

Limited Access and Awareness

Limited access to and awareness of contraceptive options remains a major barrier in the global female contraceptive market, particularly in underprivileged and rural areas. Many women face financial, cultural, or geographic constraints that prevent them from obtaining reliable contraceptives. A lack of education and knowledge about available methods also contributes to low adoption rates. Addressing this challenge requires coordinated efforts by governments, NGOs, and international health organizations to expand education campaigns and improve access to family planning services. By empowering women with accurate information and affordable options, these initiatives aim to reduce disparities and foster informed reproductive choices.

Key Market Trends

Hormonal Contraceptives with Reduced Side Effects

A significant trend shaping the female contraceptive market is the development of hormonal contraceptives designed to minimize side effects. Manufacturers are investing in research to produce solutions that effectively prevent pregnancy while reducing issues such as mood changes, weight gain, and reduced libido. These innovations aim to enhance the user experience, making hormonal contraceptives more appealing and acceptable to a broader population. As awareness of long-term reproductive health grows, demand for safer, user-friendly options is driving the evolution of new-generation hormonal contraceptives with improved tolerability and efficacy.

Key Market Players

• Bayer AG
• Mayer Laboratories Inc
• Pfizer Inc
• Mylan Pharmaceuticals Inc
• Teva Pharmaceutical Industries Ltd
• Organon & Co.
• Agile Therapeutics Inc
• Lupin Pharmaceuticals Inc
• The Female Health Company
• FUJI LATEX CO.LTD.

Report Scope:

In this report, the Global Female Contraceptive Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Female Contraceptive Market, By Contraceptive Drugs:

• Oral Contraceptives
• Contraceptive Injections
• Topical Contraceptives
• Spermicides

Female Contraceptive Market, By Device:

• Female Condoms
• Diaphragms and Caps
• Vaginal Rings
• Contraceptive Sponges
• Sub-dermal Contraceptive Implants
• Intra Uterine Contraceptive Devices (IUCDs)
• Others

Female Contraceptive Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • Germany
  • United Kingdom
  • France
  • Italy
  • Spain
• Asia-Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Female Contraceptive Market.

Available Customizations:

Global Female Contraceptive market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Female Contraceptive Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Contraceptive Drugs (Oral Contraceptives, Contraceptive Injections, Topical Contraceptives, Spermicides)
  • 5.2.2. By Device (Female Condoms, Diaphragms and Caps, Vaginal Rings, Contraceptive Sponges, Sub-dermal Contraceptive Implants, Intra Uterine Contraceptive Devices (IUCDs), Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Product Market Map
  • 5.3.1. By Contraceptive Drugs
  • 5.3.2. By Device
  • 5.3.3. By Region

6. North America Female Contraceptive Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Contraceptive Drugs (Oral Contraceptives, Contraceptive Injections, Topical Contraceptives, Spermicides)
  • 6.2.2. By Device (Female Condoms, Diaphragms and Caps, Vaginal Rings, Contraceptive Sponges, Sub-dermal Contraceptive Implants, Intra Uterine Contraceptive Devices (IUCDs), Others)
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Female Contraceptive Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Contraceptive Drugs
      • 6.3.1.2.2. By Device
  • 6.3.2. Canada Female Contraceptive Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Contraceptive Drugs
      • 6.3.2.2.2. By Device
  • 6.3.3. Mexico Female Contraceptive Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Contraceptive Drugs
      • 6.3.3.2.2. By Device

7. Europe Female Contraceptive Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Contraceptive Drugs (Oral Contraceptives, Contraceptive Injections, Topical Contraceptives, Spermicides)
  • 7.2.2. By Device (Female Condoms, Diaphragms and Caps, Vaginal Rings, Contraceptive Sponges, Sub-dermal Contraceptive Implants, Intra Uterine Contraceptive Devices (IUCDs), Others)
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Female Contraceptive Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Contraceptive Drugs
      • 7.3.1.2.2. By Device
  • 7.3.2. United Kingdom Female Contraceptive Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Contraceptive Drugs
      • 7.3.2.2.2. By Device
  • 7.3.3. France Female Contraceptive Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Contraceptive Drugs
      • 7.3.3.2.2. By Device
  • 7.3.4. Italy Female Contraceptive Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Contraceptive Drugs
      • 7.3.4.2.2. By Device
  • 7.3.5. Spain Female Contraceptive Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Contraceptive Drugs
      • 7.3.5.2.2. By Device

8. Asia-Pacific Female Contraceptive Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Contraceptive Drugs (Oral Contraceptives, Contraceptive Injections, Topical Contraceptives, Spermicides)
  • 8.2.2. By Device (Female Condoms, Diaphragms and Caps, Vaginal Rings, Contraceptive Sponges, Sub-dermal Contraceptive Implants, Intra Uterine Contraceptive Devices (IUCDs), Others)
  • 8.2.3. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Female Contraceptive Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Contraceptive Drugs
      • 8.3.1.2.2. By Device
  • 8.3.2. Japan Female Contraceptive Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Contraceptive Drugs
      • 8.3.2.2.2. By Device
  • 8.3.3. India Female Contraceptive Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Contraceptive Drugs
      • 8.3.3.2.2. By Device
  • 8.3.4. Australia Female Contraceptive Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Contraceptive Drugs
      • 8.3.4.2.2. By Device
  • 8.3.5. South Korea Female Contraceptive Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Contraceptive Drugs
      • 8.3.5.2.2. By Device

9. South America Female Contraceptive Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Contraceptive Drugs (Oral Contraceptives, Contraceptive Injections, Topical Contraceptives, Spermicides)
  • 9.2.2. By Device (Female Condoms, Diaphragms and Caps, Vaginal Rings, Contraceptive Sponges, Sub-dermal Contraceptive Implants, Intra Uterine Contraceptive Devices (IUCDs), Others)
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Female Contraceptive Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Contraceptive Drugs
      • 9.3.1.2.2. By Device
  • 9.3.2. Argentina Female Contraceptive Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Contraceptive Drugs
      • 9.3.2.2.2. By Device
  • 9.3.3. Colombia Female Contraceptive Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Contraceptive Drugs
      • 9.3.3.2.2. By Device

10. Middle East and Africa Female Contraceptive Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Contraceptive Drugs (Oral Contraceptives, Contraceptive Injections, Topical Contraceptives, Spermicides)
  • 10.2.2. By Device (Female Condoms, Diaphragms and Caps, Vaginal Rings, Contraceptive Sponges, Sub-dermal Contraceptive Implants, Intra Uterine Contraceptive Devices (IUCDs), Others)
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Female Contraceptive Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Contraceptive Drugs
      • 10.3.1.2.2. By Device
  • 10.3.2. Saudi Arabia Female Contraceptive Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Contraceptive Drugs
      • 10.3.2.2.2. By Device
  • 10.3.3. UAE Female Contraceptive Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Contraceptive Drugs
      • 10.3.3.2.2. By Device

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Development
• 12.2. Mergers & Acquisitions
• 12.3. Product Launches

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. Bayer AG
  • 14.1.1. Business Overview
  • 14.1.2. Product Offerings
  • 14.1.3. Recent Developments
  • 14.1.4. Financials (As Reported)
  • 14.1.5. Key Personnel
  • 14.1.6. SWOT Analysis
• 14.2. Mayer Laboratories Inc
• 14.3. Pfizer Inc
• 14.4. Mylan Pharmaceuticals Inc
• 14.5. Teva Pharmaceutical Industries Ltd
• 14.6. Organon & Co.
• 14.7. Agile Therapeutics Inc
• 14.8. Lupin Pharmaceuticals Inc
• 14.9. The Female Health Company
• 14.10. FUJI LATEX CO.,LTD.

15. Strategic Recommendations

16.About Us & Disclaimer